Cangrelor free acid

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561238

CAS#: 163706-06-7 (free acid)

Description: Cangrelor is a P2Y12 inhibitor, and was approved in June 2015 as an antiplatelet drug for intravenous application. Cangrelor is a high-affinity, reversible inhibitor of P2Y12 receptors that causes almost complete inhibition of ADP-induced platelet aggregate. It is a modified ATP derivative stable to enzymatic degradation. It does not require metabolic conversion to an active metabolite. This allows cangrelor’s immediate effect after infusion, and the therapeutic effects can be maintained with continuous infusion.

Chemical Structure

Cangrelor free acid
CAS# 163706-06-7 (free acid)

Theoretical Analysis

MedKoo Cat#: 561238
Name: Cangrelor free acid
CAS#: 163706-06-7 (free acid)
Chemical Formula: C17H25Cl2F3N5O12P3S2
Exact Mass: 774.9483
Molecular Weight: 776.3465
Elemental Analysis: C, 26.30; H, 3.25; Cl, 9.13; F, 7.34; N, 9.02; O, 24.73; P, 11.97; S, 8.26

Price and Availability

Size Price Availability Quantity
1.0mg USD 350.0 2 Weeks
Bulk inquiry

Related CAS #: 163706-06-7 (free acid)   163706-36-3 (sodium)    

Synonym: Cangrelor free acid; AR-C69931MX; AR C69931MX; ARC69931MX; AR-C69931; AR C69931; ARC69931;

IUPAC/Chemical Name: (dichloro((((((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-((2-(methylthio)ethyl)amino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)methyl)phosphonic acid


InChi Code: InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1

SMILES Code: CSCCNC1=NC(SCCC(F)(F)F)=NC2=C1N=CN2[C@@H]3O[C@@H]([C@H]([C@H]3O)O)COP(O)(OP(O)(C(Cl)(Cl)P(O)(O)=O)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 776.3465 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Bhattad VB, Gaddam S, Lassiter MA, Jagadish PS, Ardeshna D, Cave B, Khouzam RN. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med. 2019 Sep;7(17):408. doi: 10.21037/atm.2019.07.64. Review. PubMed PMID: 31660307; PubMed Central PMCID: PMC6787394.

2: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from PubMed PMID: 31643758.

3: Loffi M, Galeazzi G, Di Tano G, Pedroni P, Passamonti E. Who was the culprit? Non-ST-elevation acute coronary syndrome treated with percutaneous coronary intervention and cangrelor infusion. Minerva Cardioangiol. 2019 Oct;67(5):439-442. doi: 10.23736/S0026-4725.19.04916-8. PubMed PMID: 31637900.

4: Gernhofer YK, Banks DA, Golts E, Pretorius V. Novel Use of Cangrelor With Heparin During Cardiopulmonary Bypass in Patients With Heparin-Induced Thrombocytopenia Who Require Cardiovascular Surgery: A Case Series. Semin Thorac Cardiovasc Surg. 2019 Oct 11. pii: S1043-0679(19)30318-1. doi: 10.1053/j.semtcvs.2019.10.002. [Epub ahead of print] PubMed PMID: 31610233.

5: Ciolek AM, Ma K, Garan AR, Eisenberger AB, Jennings DL. Use of cangrelor during venoarterial extracorporeal membrane oxygenation following percutaneous coronary intervention. Artif Organs. 2019 Oct 10. doi: 10.1111/aor.13563. [Epub ahead of print] PubMed PMID: 31602658.

6: Cereda AF, Morici N, Aseni P, Chiara O. Cangrelor bridging strategy for liver damage after mechanical chest compression. Anatol J Cardiol. 2019 Sep;22(4):E8-E9. doi: 10.14744/AnatolJCardiol.2019.78546. PubMed PMID: 31584440.

7: Tanaka KA, Henderson R, Williams B. Heparin-Induced Thrombocytopenia and Cardiac Surgery: Can We Do It All With Cangrelor? A A Pract. 2019 Nov 1;13(9):366. doi: 10.1213/XAA.0000000000001094. PubMed PMID: 31567127; PubMed Central PMCID: PMC6818991.

8: Scala E, Pitta-Gros B, Pantet O, Iafrate M, Kirsch M, Marcucci C, Alberio L. Cardiac Surgery Successfully Managed With Cangrelor in a Patient With Persistent Anti-PF4/Heparin Antibodies 8 Years After Heparin-Induced Thrombocytopenia. J Cardiothorac Vasc Anesth. 2019 Nov;33(11):3073-3077. doi: 10.1053/j.jvca.2019.06.044. Epub 2019 Jul 6. PubMed PMID: 31420311.

9: Abdennour L, Sourour N, Drir M, Premat K, Shotar E, Taylor G, Godier A, Mathout J, Lenck S, Bernard R, Carpentier A, Degos V, Clarençon F. Preliminary Experience with Cangrelor for Endovascular Treatment of Challenging Intracranial Aneurysms. Clin Neuroradiol. 2019 Jul 15. doi: 10.1007/s00062-019-00811-2. [Epub ahead of print] PubMed PMID: 31309241.

10: Yong CM, Sundaram V, Abnousi F, Olivier CB, Yang J, Stone GW, Steg PG, Michael Gibson C, Hamm CW, Price MJ, Deliargyris EN, Prats J, White HD, Harrington RA, Bhatt DL, Mahaffey KW; CHAMPION PHOENIX Investigators. The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. Clin Cardiol. 2019 Jun 29. doi: 10.1002/clc.23221. [Epub ahead of print] PubMed PMID: 31254472; PubMed Central PMCID: PMC6727881.

11: Ubaid S, Ford TJ, Berry C, Murray HM, Wrigley B, Khan N, Thomas MR, Armesilla AL, Townend JN, Khogali SS, Munir S, Martins J, Hothi SS, McAlindon EJ, Cotton JM. Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial. Thromb Haemost. 2019 Jul;119(7):1171-1181. doi: 10.1055/s-0039-1688789. Epub 2019 May 26. PubMed PMID: 31129911.

12: Chen Y, Bernardo NL, Waksman R. Cangrelor for the Rescue of Intra-Procedural Stent Thrombosis in Percutaneous Coronary Intervention. Cardiovasc Revasc Med. 2019 Jul;20(7):624-625. doi: 10.1016/j.carrev.2019.04.018. Epub 2019 Apr 24. PubMed PMID: 31088721.

13: Morici N, Nava S, Sacco A, Viola G, Oreglia J, Meani P, Oliva F, Ranucci M, Leonardi S, Rossini R. Acute myocardial infarction complicating ischemic stroke: is there room for cangrelor? Platelets. 2019 May 8:1-4. doi: 10.1080/09537104.2019.1609663. [Epub ahead of print] PubMed PMID: 31066332.

14: Godier A, Mesnil M, De Mesmay M, Dagois S, Thion LA, Dupont C, Mazighi M, Devys JM. Bridging antiplatelet therapy with cangrelor in patients with recent intracranial stenting undergoing invasive procedures: a prospective case series. Br J Anaesth. 2019 Jul;123(1):e2-e5. doi: 10.1016/j.bja.2019.03.019. Epub 2019 Apr 19. PubMed PMID: 31010645.

15: Guvvala V, Chidambaram Subramanian V, Anireddy JS. A study on structural characterization of degradation products of cangrelor using LC/QTOF/MS/MS and NMR. J Pharm Biomed Anal. 2019 Jun 5;170:327-334. doi: 10.1016/j.jpba.2019.03.031. Epub 2019 Mar 28. PubMed PMID: 30978606.

16: Erlinge D. Cangrelor for ST-Segment-Elevation Myocardial Infarction. Circulation. 2019 Apr 2;139(14):1671-1673. doi: 10.1161/CIRCULATIONAHA.119.039253. PubMed PMID: 30933619.

17: Lu H, Guan W, Zhou Y, Tang Z, Bao H. Cangrelor or Clopidogrel in Patients with Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials. Diabetes Ther. 2019 Jun;10(3):937-950. doi: 10.1007/s13300-019-0593-7. Epub 2019 Mar 23. PubMed PMID: 30905057; PubMed Central PMCID: PMC6531549.

18: Hu TY, Peeters SM, Nagasawa DT, Kamdar NV, Brook RP, Sun J, Park S, Moreland NC, Cruz D, Macyszyn L, Press MC. Cangrelor Bridging Within 6 Months of a Drug-Eluting Stent in a Patient for Emergency Cervical Spine Surgery: A Case Report. A A Pract. 2019 Jul 15;13(2):69-73. doi: 10.1213/XAA.0000000000000994. PubMed PMID: 30864953.

19: Droppa M, Vaduganathan M, Venkateswaran RV, Singh A, Szumita PM, Roberts RJ, Qamar A, Hack L, Rath D, Gawaz M, Fuernau G, de Waha-Thiele S, Desch S, Schneider S, Ouarrak T, Jaffer FA, Zeymer U, Thiele H, Bhatt DL, Geisler T. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y(12) inhibition from the IABP-SHOCK II trial. Resuscitation. 2019 Apr;137:205-212. doi: 10.1016/j.resuscitation.2019.02.008. Epub 2019 Feb 18. PubMed PMID: 30790690.

20: Hideo-Kajita A, Rogers T, Buchanan K, Iantorno M, Gajanana D, Ozaki Y, Dan K, Kolm P, Brathwaite E, Beyene S, Melaku G, Meirovich Y, Dheendsa A, Garcia-Garcia HM, Torguson R, Waksman R. Effects of Cangrelor as Adjunct Therapy to Percutaneous Coronary Intervention. Am J Cardiol. 2019 Apr 15;123(8):1228-1238. doi: 10.1016/j.amjcard.2019.01.031. Epub 2019 Jan 25. PubMed PMID: 30738570.